Crescent Biopharma Inc (Pre-Reincorporation) is a US-based company operating in Biotechnology industry. The company is headquartered in Rockville, Maryland and currently employs 4 full-time employees. Crescent Biopharma Inc., formerly GlycoMimetics, Inc., is a biotechnology company. The firm is engaged in advancing novel precision-engineered molecules to advance care for patients with solid tumors. The Company’s lead program is CR-001, a tetravalent PD-1 x VEGF bispecific antibody in development for the treatment of solid tumors, and it is also advancing CR-002 and CR-003, antibody drug conjugates (ADCs) with topoisomerase inhibitor payloads for undisclosed targets. CR-002 and CR-003 are ADCs designed to deliver clinically active cytotoxic drugs known as topoisomerase inhibitors to tumor cells. Each of these programs has the potential to deliver therapeutics with clinical efficacy both as a monotherapy and in combination with CR-001 with significant potential across solid tumor indications.
The current price of CBIO is $0, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Crescent Biopharma Inc?
Crescent Biopharma Inc belongs to Biotechnology industry and the sector is Health Care
What is Crescent Biopharma Inc market cap?
Crescent Biopharma Inc's current market cap is $NaN
Is Crescent Biopharma Inc a buy, sell, or hold?
According to wall street analysts, 8 analysts have made analyst ratings for Crescent Biopharma Inc, including 5 strong buy, 7 buy, 1 hold, 0 sell, and 5 strong sell